Royce & Associates LP cut its stake in MEDNAX Inc (NYSE:MD) by 17.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,797 shares of the company’s stock after selling 580 shares during the period. Royce & Associates LP’s holdings in MEDNAX were worth $78,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. increased its position in shares of MEDNAX by 56.2% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the company’s stock valued at $40,000 after purchasing an additional 638 shares during the last quarter. Parallel Advisors LLC increased its holdings in MEDNAX by 78.4% in the third quarter. Parallel Advisors LLC now owns 1,993 shares of the company’s stock valued at $45,000 after buying an additional 876 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in MEDNAX in the fourth quarter valued at $166,000. Robeco Institutional Asset Management B.V. acquired a new stake in MEDNAX in the third quarter valued at $161,000. Finally, Stevens Capital Management LP acquired a new stake in MEDNAX in the fourth quarter valued at $205,000. 87.55% of the stock is owned by hedge funds and other institutional investors.
NYSE MD traded down $0.97 on Friday, reaching $19.99. The stock had a trading volume of 3,222,892 shares, compared to its average volume of 1,157,647. The stock has a market cap of $1.77 billion, a P/E ratio of -1.11, a price-to-earnings-growth ratio of 0.82 and a beta of 0.84. MEDNAX Inc has a 12-month low of $19.45 and a 12-month high of $36.35. The business’s 50-day moving average price is $26.10 and its 200 day moving average price is $24.50. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.93 and a current ratio of 1.43.
MEDNAX (NYSE:MD) last announced its earnings results on Thursday, February 20th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.08. The business had revenue of $905.38 million for the quarter, compared to analyst estimates of $900.85 million. MEDNAX had a negative net margin of 42.63% and a positive return on equity of 12.22%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the firm posted $0.92 earnings per share. On average, sell-side analysts predict that MEDNAX Inc will post 3 earnings per share for the current year.
A number of analysts have weighed in on the stock. Stifel Nicolaus raised shares of MEDNAX from a “hold” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $33.00 in a report on Thursday, December 12th. Mizuho lowered their target price on shares of MEDNAX from $25.00 to $22.00 and set a “neutral” rating for the company in a report on Friday. Citigroup dropped their target price on shares of MEDNAX from $29.00 to $23.00 and set a “neutral” rating on the stock in a research report on Friday. SunTrust Banks lifted their price target on shares of MEDNAX from $27.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Finally, Deutsche Bank assumed coverage on shares of MEDNAX in a research note on Friday, January 3rd. They set a “hold” rating and a $34.00 price target on the stock. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $26.58.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Read More: What is a back-end load?
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.